QLQiong Lin

Qiong Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qiong Lin has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Dalu Cheng

    Department of Clinical Medicine Fujian Medical University Fuzhou Fujian China

    1 shared publication
  • Gang Chen

    Department of orthopedics Fujian Medical University Union Hospital Fuzhou Fujian China

    1 shared publication
  • Jiandong Li

    Department of orthopedics Fujian Medical University Union Hospital Fuzhou Fujian China

    1 shared publication
  • Jingjing Gong

    Department of Cardiology The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian China

    1 shared publication
  • Penghong Chen

    Department of Plastic Surgery The Second Affiliated Hospital of Fujian Medical University Fuzhou Fujian China

    1 shared publication
  • Zhitao Shangguan

    Department of orthopedics Fujian Medical University Union Hospital Fuzhou Fujian China

    1 shared publication

Latest Publications

  • Open Access

    Prodh2‐Mediated Mitochondrial Stress Drives TNF ‐α‐Induced Myoblast Dysfunction and Sarcopenia in COPD

    by Gang Chen, Zhitao Shangguan, Jingjing Gong, Dalu Cheng, Penghong Chen, Jiandong Li, Qiong Lin

    Sarcopenia in chronic obstructive pulmonary disease (COPD) is driven by elevated tumor necrosis factor‐alpha (TNF‐α), yet the underlying mechanism remains unclear. Here, we identify the mitochondrial metabolic enzyme Prodh2 as a pivotal mediator. Prodh2 was significantly upregulated in sarcopenic COPD patients and a corresponding mouse model. Mechanistically, TNF‐α induced Prodh2 transcription in myoblasts via a p53‐dependent pathway. This upregulation triggered excessive mitochondrial reactive oxygen species, leading to the release of mitochondrial DNA (mtDNA). Cytosolic mtDNA subsequently activated the cGAS/STING innate immune pathway, causing myoblast apoptosis, proliferation arrest, and atrophy. While Prodh2 knockdown reversed these effects in vitro, muscle‐specific knockdown of Prodh2 in vivo critically ameliorated muscle atrophy and restored strength. Our study unveils a novel TNF‐α‐p53‐Prodh2‐cGAS/STING axis that links chronic inflammation to sarcopenia through metabolic‐immune crosstalk, validating Prodh2 as a promising therapeutic target.